| アブストラクト | BACKGROUND: Miscarriage is a common and serious adverse pregnancy outcome. Assessing drug-associated miscarriage risk is essential for medication safety in pregnancy. Using the FDA Adverse Event Reporting System this study systematically mined adverse drug events related to miscarriage and combined machine learning with explainable Artificial Intelligence to evaluate potential high-risk drugs. METHODS: We retrieved FAERS reports of miscarriage-associated ADEs from 2005 to 2024. Disproportionality analyses were conducted using the reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and Multi-Item Gamma Poisson Shrinker (MGPS), with subgroup analyses by age and body weight. An eXtreme Gradient Boosting (XGBoost) model was developed to predict miscarriage risk, and Shapley Additive exPlanations (SHAP) were used to interpret feature contributions. Finally, Weibull distribution modeling characterized the time-to-onset (TTO) from drug exposure to miscarriage. RESULTS: A total of 36,389 ADEs were included. We identified several potential high-risk classes, notably immunomodulators, psychoactive/neuroactive agents, and antimicrobials. The XGBoost model showed favorable discrimination with a mean area under the curve (AUC) of 0.738. SHAP analysis reveals that immunomodulatory factors, such as adalimumab and infliximab, are significant predictors of miscarriage events in this model. The distribution of their SHAP values suggests a strong association between these drugs and miscarriage reports. time-to-onset analyses suggested that most miscarriages occurred within 2 years after drug exposure, with marked heterogeneity in risk timing across agents; anti-Tumor Necrosis Factor-alpha drugs (TNF-alpha) exhibited a higher early risk. CONCLUSION: Machine learning and SHAP interpretability analysis based on the FAERS database effectively identified immunomodulators, antiviral drugs, and psychiatric/neuropsychiatric medications as potential risk signals associated with miscarriage. These findings underscore the need for individualized medication assessment that considers patient age and body weight, providing evidence-based guidance and early alerting for reference for drug risk assessment during pregnancy. |
|---|
| ジャーナル名 | Frontiers in pharmacology |
|---|
| Pubmed追加日 | 2026/3/11 |
|---|
| 投稿者 | Lin, Sen; Ma, Lanyue; Zhao, Ruiqi; Peng, Lisheng; Zhang, Xinyu; Zhang, Bei; Li, Danfei; Li, Yijia; He, Li |
|---|
| 組織名 | Department of Oncology and Hematology, Shenzhen Traditional Chinese Medicine;Hospital, Shenzhen, China.;The Fourth Clinical Medical College, Guangzhou University of Chinese Medicine,;Shenzhen, China.;Department of Hepatology, Shenzhen Municipal Hospital of Traditional Chinese;Medicine, Shenzhen, China. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/41808870/ |
|---|
